While pharma has historically been hesitant to change its development and manufacturing processes lest they fall out of compliance with the industry’s strict regulatory standards, new environmental regulations, combined with emerging business incentives, are shifting the industry’s mindset. Recognizing the industry’s need to seamlessly integrate sustainability performance into R&D and production processes, new innovations seek to help pharma experts converge sustainability choices with other operational decisions.

The pact grants Ipsen the option to acquire the rights to two small molecule candidates pursued under the collaboration.

As part of the $380 million deal, Cellares will tech-transfer select BMS CAR T-cell therapies onto its end-to-end fully automated manufacturing platform.

mRNA-LNP manufacturing is fraught with obstacles, resulting in higher program risk, inflated costs, and delayed market release. With the right knowledge, companies can overcome the challenges to de-risk & optimize the path to manufacturing success.